Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anton Burkhard-Meier

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Infection|April 9, 2024
Sapovirus: an emerging pathogen in kidney transplant recipients?Michaela Rippl, Anton Burkhard-Meier, Ulf Schönermarck, et al.
Laryngo- Rhino- Otologie|December 21, 2022
[Cannabis in oncology - much ado about nothing?]Anton Burkhard-Meier, Constanze Rémi, Lars H Lindner, et al.
Deutsche Medizinische Wochenschrift (1946)|February 27, 2024
[Current therapeutic standards in advanced soft tissue sarcomas]Anton Burkhard-Meier, Luc M Berclaz, Dorit Di Gioia, et al.
Deutsche Medizinische Wochenschrift (1946)|July 22, 2022
[Cannabis in oncology - much ado about nothing?]Anton Burkhard-Meier, Constanze Rémi, Lars H Lindner, et al.
Anti-Cancer Drugs|October 7, 2022
Treatment of metastatic alveolar soft part sarcoma with axitinib and pembrolizumab in an 80-year-old patient with a history of autoimmune disordersKlara Dorman, Anton Burkhard-Meier, Dorit Di Gioia, et al.
Annals of Surgical Oncology|August 29, 2025
Surgery for Retroperitoneal Soft Tissue Sarcoma is Safe Following Multimodal Treatment with Regional HyperthermiaMathilda Knoblauch, Cathy Werdel, Yanik Arlt, et al.
Cancers|June 22, 2023
TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)Luc M Berclaz, Annelore Altendorf-Hofmann, Lars H Lindner, et al.
Journal of Cancer Research and Clinical Oncology|August 5, 2023
Implementing precision oncology for sarcoma patients: the CCC<sup>LMU</sup>molecular tumor board experienceLuc M Berclaz, Anton Burkhard-Meier, Philipp Lange, et al.
BMC Cancer|April 11, 2025
The impact of CT-based adipose tissue distribution and sarcopenia on treatment outcomes in patients with high-risk soft tissue sarcomaLuc M Berclaz, Dorit Di Gioia, Michael Völkl, et al.
BMC Cancer|March 19, 2025
LDH and hemoglobin outperform systemic inflammatory indices as prognostic factors in patients with soft tissue sarcoma undergoing neoadjuvant treatmentLuc M Berclaz, Dorit Di Gioia, Vindi Jurinovic, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Infection|April 9, 2024
Sapovirus: an emerging pathogen in kidney transplant recipients?Michaela Rippl, Anton Burkhard-Meier, Ulf Schönermarck, et al.
Laryngo- Rhino- Otologie|December 21, 2022
[Cannabis in oncology - much ado about nothing?]Anton Burkhard-Meier, Constanze Rémi, Lars H Lindner, et al.
Deutsche Medizinische Wochenschrift (1946)|February 27, 2024
[Current therapeutic standards in advanced soft tissue sarcomas]Anton Burkhard-Meier, Luc M Berclaz, Dorit Di Gioia, et al.
Deutsche Medizinische Wochenschrift (1946)|July 22, 2022
[Cannabis in oncology - much ado about nothing?]Anton Burkhard-Meier, Constanze Rémi, Lars H Lindner, et al.
Anti-Cancer Drugs|October 7, 2022
Treatment of metastatic alveolar soft part sarcoma with axitinib and pembrolizumab in an 80-year-old patient with a history of autoimmune disordersKlara Dorman, Anton Burkhard-Meier, Dorit Di Gioia, et al.
Annals of Surgical Oncology|August 29, 2025
Surgery for Retroperitoneal Soft Tissue Sarcoma is Safe Following Multimodal Treatment with Regional HyperthermiaMathilda Knoblauch, Cathy Werdel, Yanik Arlt, et al.
Cancers|June 22, 2023
TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)Luc M Berclaz, Annelore Altendorf-Hofmann, Lars H Lindner, et al.
Journal of Cancer Research and Clinical Oncology|August 5, 2023
Implementing precision oncology for sarcoma patients: the CCC<sup>LMU</sup>molecular tumor board experienceLuc M Berclaz, Anton Burkhard-Meier, Philipp Lange, et al.
BMC Cancer|April 11, 2025
The impact of CT-based adipose tissue distribution and sarcopenia on treatment outcomes in patients with high-risk soft tissue sarcomaLuc M Berclaz, Dorit Di Gioia, Michael Völkl, et al.
BMC Cancer|March 19, 2025
LDH and hemoglobin outperform systemic inflammatory indices as prognostic factors in patients with soft tissue sarcoma undergoing neoadjuvant treatmentLuc M Berclaz, Dorit Di Gioia, Vindi Jurinovic, et al.
Pageof 2